Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge conference assessing opportunities for combination therapy Journal Article
| Authors: | Lynch, T. J. Jr; Blumenschein, G. R. Jr; Engelman, J. A.; Espinoza-Delgado, I.; Govindan, R.; Hanke, J.; Hanna, N. H.; Heymach, J. V.; Hirsch, F. R.; Jänne, P. A.; Lilenbaum, R. C.; Natale, R. B.; Riely, G. J.; Sequist, L. V.; Shapiro, G. I.; Shaw, A.; Shepherd, F. A.; Socinski, M.; Sorensen, A. G.; Wakelee, H. A.; Weitzman, A. |
| Article Title: | Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge conference assessing opportunities for combination therapy |
| Abstract: | The promise of effective targeted therapy for lung cancer requires rigorous identification of potential targets combined with intensive discovery and development efforts aimed at developing effective "drugs" for these targets. We now recognize that getting the right drug to the right target in the right patient is more complicated than one could have imagined a decade ago. As knowledge of targets and development of agents have proliferated and advanced, so too have data demonstrating the biologic heterogeneity of tumors. The finding that lung cancers are genetically diverse and can exhibit several pathways of resistance in response to targeted agents makes the prospect for curative therapy more daunting. It is becoming increasingly clear that single-agent treatment will be the exception rather than the rule. This information raises important new questions about the development and assessment of novel agents in lung cancer treatment: (1) How do we identify the most important drug targets for tumor initiation and maintenance? (2) What is the best way to assess drug candidates that may only be relevant in a small fraction of patients? (3) What models do we use to predict clinical response and identify effective combinations? And (4) how do we bring combination regimens to the clinic, particularly when the agents are not yet approved individually and may be under development from different companies? The Fifth Cambridge Conference on Novel Agents in the Treatment of Lung Cancer was held in Cambridge, Massachusetts, on October 1-2, 2007, to discuss these questions by reviewing recent progress in the field and advancing recommendations for research and patient care. New information, conclusions, and recommendations considered significant for the field by the program faculty are summarized here and presented at greater length in the individual articles and accompanying discussions that comprise the full conference proceedings. A CME activity based on this summary is also available at www.informedicalcme.com/cme. © 2008International Association for the Study of Lung Cancer. |
| Keywords: | signal transduction; cancer chemotherapy; cancer survival; treatment outcome; treatment response; vascular endothelial growth factor a; gene mutation; clinical trial; fatigue; sorafenib; angiogenesis inhibitor; bevacizumab; cisplatin; erlotinib; sunitinib; cancer growth; diarrhea; drug withdrawal; hypertension; monotherapy; patient selection; unspecified side effect; drug approval; conference paper; drug targeting; gemcitabine; paclitaxel; nuclear magnetic resonance imaging; positron emission tomography; antineoplastic agent; protein function; gastrointestinal stromal tumor; imatinib; carboplatin; cancer immunotherapy; controlled clinical trial; bone marrow suppression; lung non small cell cancer; mucosa inflammation; nausea; randomized controlled trial; antineoplastic combined chemotherapy protocols; carcinoma, non-small-cell lung; lung neoplasms; genotype; randomized controlled trials as topic; lung cancer; combination chemotherapy; tumor biopsy; receptor, epidermal growth factor; angiogenesis; neovascularization, pathologic; wild type; cetuximab; kidney carcinoma; docetaxel; protein tyrosine kinase inhibitor; drug delivery systems; lung small cell cancer; fluorescence in situ hybridization; drug mechanism; melanoma antigen 3; gefitinib; cediranib; vandetanib; nuclear magnetic resonance spectroscopy; 17 demethoxy 17 (2 dimethylaminoethylamino)geldanamycin; heat shock protein 90 inhibitor; tanespimycin; platinum; contrast medium; egfr; vegf; hemoptysis; tanespimycin hydroquinone; geldanamycin; 4 [3 chloro 4 (2 pyridinylmethoxy)anilino] 3 cyano 6 (4 dimethylaminocrotonamido) 7 ethoxyquinoline; drug intermittent therapy; xl 647; biopsies; profiling; phosphatidylethanolamine binding protein; novel targets; cpg 7909; congenital skin disease |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 3 |
| Issue: | 6 SUPPL 2 |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2008-06-01 |
| Start Page: | S107 |
| End Page: | S112 |
| Language: | English |
| DOI: | 10.1097/JTO.0b013e318174e9d3 |
| PUBMED: | 18520291 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 7" - "Export Date: 17 November 2011" - "Source: Scopus" |
